The research team, led by Annette Binder of the Section for Addiction Medicine and Addiction Research, conducted 35 in-depth interviews across Germany between November 2020 and April 2021. The sample comprised narrative interviews with 10 relatives, 11 patients undergoing formal proof of abstinence, and 3 former patients who had discontinued the transplantation process, complemented by semi-structured interviews with 11 healthcare professionals drawn from 10 of the 22 German centers performing liver transplantation at the time. All interviews were audio-recorded, transcribed verbatim, and analyzed using qualitative content analysis with MAXQDA software. Because patients and relatives were interviewed separately in one-on-one settings, the researchers were able to compare perspectives within families and identify where experiences converged and where they diverged. Recruitment continued until thematic saturation was reached, meaning that further interviews no longer produced substantially new insights. The team applied the framework of Lincoln and Guba to ensure credibility, dependability, confirmability, transferability, and authenticity, and used the Integrated Model of Advanced Liver Disease by Naik and colleagues as a sensitizing concept to guide attention toward relevant phenomena.

The central finding is stark: relatives do far more than provide comfort. They function as de facto nurses, pharmacists, dietitians, appointment schedulers, and medical translators. One wife described the routine plainly: “Preparing the medication and, yeah, you have to keep an eye on everything.” Patients themselves frequently acknowledged that without this support they would have failed. “That’s when I said: Yes, I wouldn’t have made it on my own. If I had been completely alone, I wouldn’t have made it,” one patient in treatment reported. The practical dimension of care included arranging and supporting attendance at medical appointments, managing complex medication regimens, enforcing dietary requirements associated with cirrhosis, and structuring daily life around the maintenance of alcohol abstinence. These tasks collectively constitute the operational backbone of the six-month abstinence verification period, a phase in which any slip in adherence can disqualify a patient from listing entirely.

Beyond logistics, the study documented a striking asymmetry in health literacy. Relatives systematically took on the responsibility of learning about cirrhosis, transplantation medicine, and the organizational structures of the healthcare system, often immersing themselves in the subject and making countless calls to hospitals and physicians. For many, this active knowledge acquisition served a second psychological function: it generated a sense of self-efficacy, a feeling that they could actually influence the outcome. “For me, it was really good to take action and engage with the topic — it gave me a bit of a feeling that I could actually do something,” explained one adult child of a patient. Patients, by contrast, tended toward a passive role, deferring information gathering and communication with clinicians to their family members. “And of course, I’m really glad that my wife took charge of everything. She’s probably going to become a liver specialist one day,” one patient quipped. The authors note that this passivity may reflect avoidance of confronting the potential consequences of the illness, or cognitive limitations caused by advanced liver disease itself—a known phenomenon, since prior research has documented critical misconceptions and knowledge gaps among patients with alcohol-related liver disease.

Motivation emerged as another domain in which family proved decisive. The most powerful driver of sustained abstinence reported by patients was the desire to remain present for their children and grandchildren, to watch them grow up. “If things had continued the way they were, I wouldn’t have been around to see them grow up. That really had a big impact on me,” one patient reflected. Relatives reinforced this motivation in tangible ways: removing alcohol from the household, abstaining from drinking in the patient’s presence, and openly celebrating the abstinence achieved. Healthcare professionals interviewed for the study confirmed this dynamic from the clinical side, noting that family pride in a patient’s sobriety functions as a stabilizing force, while relatives who themselves drink regularly and lack understanding of the difficulty of maintaining abstinence may be considerably less capable of providing effective support. Notably, adult children who cared for affected parents described a reversal of roles—suddenly needing to be emotionally strong and to represent their parent’s interests, a burden the parents themselves rarely acknowledged.

The emotional dimension of this support was equally consequential. Patients emphasized unconditional support, daily check-ins, and open communication about feelings as essential to coping with the listing process, and some families even reported that communication and relationships improved after the diagnosis. Yet the study also uncovered a sobering counterpoint: the psychosocial needs of the relatives themselves were systematically neglected. Many described the caregiving as exhausting, with time demands restricting their personal lives and their energy resources reaching their limits. “Because I know that my energy is limited, too,” one wife said simply. Some longed for a brief escape, even a vacation; older parents caring for affected adult children reported their own quality of life deteriorating. Patients, for their part, tended to accept their relatives’ sacrifice uncritically or even to welcome it—one praised his wife for how “wonderfully” she sacrificed herself. Relatives said they had received neither organizational support nor the opportunity for supportive therapeutic conversations of their own.

The perspective of healthcare professionals added a systemic layer to these findings. Transplant clinicians regard pre-listing family support as a strong predictor of continued support after surgery, which matters because long-term immunosuppressive medication adherence, regular follow-up attendance, and sustained abstinence remain critical for graft survival after transplantation. “After the operation, patients are physically weakened, need to take medication consistently, and must remain abstinent in the long term,” one psychosomatic physician explained. Paradoxically, however, the professionals also reported that therapeutic or supportive conversations for relatives are generally not offered at their centers, and that relatives frequently arrive in a state of crisis themselves, unable to recognize their own needs without professional guidance. Children of patients were identified as being particularly burdened by this double role of caregiver and crisis sufferer.

Building on these results, the researchers propose an expanded theoretical framework: the Family-Focused IMALD Model for Liver Transplantation (FF-IMALD-LTX), an adaptation of Naik and colleagues’ Integrated Model of Advanced Liver Disease. Whereas the original model positions family members as supportive figures alongside the patient, the new model elevates them to a central element conceptualized as “Informed, Supporting & Well-Supported Relatives.” The conceptual shift is significant: it implies that transplant programs should not merely assess social support during psychosocial evaluation, as current German, European, and American guidelines recommend, but should actively strengthen it, identify unmet needs among caregivers, and provide them with resources and information. For patients without close relatives, the authors argue, these supportive functions may need to be delivered through professional or peer-based structures, underscoring the need for flexible and inclusive care pathways.

The findings align with prior evidence from related fields. Earlier qualitative work on early liver transplantation for severe alcohol-associated liver disease found that patients struggled to navigate the medical system, and that lack of support often delayed referral to transplant centers. Studies of the post-transplant period have shown that family members are essential to self-management, medication adherence, and the practical implementation of dietary recommendations. Research on caregiver well-being in end-stage liver disease has documented diminished well-being among informal care partners, and a scoping review identified social isolation as a risk factor for post-transplant alcohol relapse. The Tübingen study also connects to the Community Reinforcement and Family Training (CRAFT) approach, an evidence-based method in which positive reinforcement from concerned significant others supports behavioral change in individuals with alcohol dependence; the recognition and celebration of abstinence by family members observed in this study mirrors a core CRAFT mechanism.

The authors acknowledge limitations, including potential self-selection bias among motivated participants, reliance on self-report susceptible to social desirability effects, a modest professional sample, and confinement to a single national healthcare context, which may limit transferability to countries with different transplant systems. Nevertheless, the study offers compelling initial evidence that the six-month abstinence requirement, often criticized on clinical and ethical grounds, is in practice a family undertaking as much as an individual one. As organ scarcity keeps transplant lists short and evaluation criteria strict, the message for clinicians is unambiguous: systematically integrating relatives into clinical pathways, addressing caregiver burden, and offering family-centered interventions such as CRAFT-informed support may improve not only patient stability and transplant eligibility but also the well-being of the invisible caregivers on whom the entire process quietly depends.

The modern classification of steatotic liver disease includes metabolic dysfunction-associated steatotic liver disease, metabolic and alcohol-related liver disease, and alcohol-related liver disease. Although these labels are clinically useful, they do not always reflect the reality experienced by patients. Many people have obesity, type 2 diabetes, hypertension or dyslipidaemia while also consuming alcohol at levels that may influence liver injury. Instead of occupying separate categories, these factors frequently overlap and form a continuous spectrum of risk.

At the centre of this spectrum are cardiometabolic risk factors, or CMRFs. Excess body weight, insulin resistance, abnormal blood lipids, elevated blood pressure and type 2 diabetes can each contribute to hepatic fat accumulation and inflammation. When several are present together, their effects may be synergistic rather than merely additive. Metabolic dysfunction can increase the liver’s vulnerability to alcohol, while alcohol can intensify the biological consequences of obesity and diabetes, creating conditions that promote progressive scarring.

The most serious consequence of this interaction is fibrosis, the accumulation of scar tissue caused by repeated or persistent liver injury. Fibrosis can advance silently for years before cirrhosis develops, and symptoms may remain absent until liver function is substantially impaired. In patients exposed to both metabolic stress and alcohol, progression may be accelerated, increasing the risk of cirrhosis, liver failure and liver-related death. The authors therefore emphasize that alcohol exposure should not be assessed independently from a patient’s metabolic health.

A further challenge is that both alcohol intake and cardiometabolic risk are dynamic. A person’s drinking pattern may increase or decrease, while body weight, blood glucose, blood pressure and lipid levels can change in response to age, illness, medication or lifestyle. These changes may move an individual from one part of the steatotic liver disease spectrum to another. A diagnosis based on a single assessment may consequently become outdated, particularly when clinical decisions depend on rigid thresholds.

Misclassification is also common because alcohol consumption is often under-reported or difficult to quantify accurately. Patients may forget the amount they drink, underestimate serving sizes or avoid disclosure because of stigma. Clinicians, meanwhile, may rely on brief questionnaires that do not fully capture binge drinking, irregular consumption or changes over time. The researchers point to phosphatidylethanol, commonly known as PEth, as an objective biomarker that can help identify recent alcohol exposure. PEth is formed in red blood cells in the presence of alcohol and may provide an important complement to confidential clinical conversations rather than replacing them.

The proposed solution is an integrated form of risk stratification. Instead of asking whether a patient fits a single category, clinicians would systematically evaluate alcohol exposure, cardiometabolic risk and the extent of liver fibrosis. Non-invasive fibrosis assessments, including blood-based scores and imaging techniques that measure liver stiffness, can help identify people at higher risk without immediately requiring a biopsy. Repeated testing is particularly important because the underlying drivers of disease can evolve, altering a patient’s prognosis and treatment needs.

Management under this framework would also be multidimensional. Alcohol reduction or cessation support should be offered alongside intensive treatment of obesity, diabetes, hypertension and dyslipidaemia. Depending on the degree of liver injury, care may involve hepatologists, primary-care physicians, endocrinologists, dietitians, addiction specialists and mental-health professionals. The goal is not simply to reduce fat in the liver, but to interrupt the biological processes that lead to inflammation, fibrosis and cardiovascular complications, which are major causes of illness in people with steatotic liver disease.

The need for a broader approach is becoming more urgent as new liver-directed medicines enter clinical development and practice. Many emerging therapies for metabolic dysfunction-associated steatohepatitis have excluded people with concurrent alcohol use from clinical trials. As a result, the populations studied in trials may not resemble the diverse patients seen in real-world clinics, where metabolic disease and alcohol exposure often coexist. The authors argue that future research and treatment pathways should better reflect this complexity. A spectrum-based model, supported by repeated reassessment and objective measurements where appropriate, could offer a more accurate and equitable way to manage one of the world’s most widespread chronic liver conditions.

Subject of Research: Steatotic liver disease, metabolic and alcohol-related liver risks, cardiometabolic risk factors, fibrosis assessment and integrated patient management.

Article Title: The dynamic spectrum of steatotic liver disease: the global perspective

Article References: Younossi, Z.M., Zelber-Sagi, S., Kalligeros, M. et al. “The dynamic spectrum of steatotic liver disease: the global perspective.” Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01235-3

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01235-3

Keywords: Steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, cardiometabolic risk factors, fibrosis, cirrhosis, phosphatidylethanol, liver health.

Recent genome-wide association studies (GWAS) have made significant strides in identifying common genetic variants linked to steatotic liver diseases. One standout find is the variant known as PNPLA3 I148M, which has emerged as the most potent genetic determinant across varying disease phenotypes. This particular variant highlights the intricate relationship between genetic predisposition and lipid metabolism, emphasizing how variations at the genomic level can manifest in distinct clinical outcomes for individuals.

Beyond the well-known genetic variants, the shared genetic architecture seen in both metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease suggests that converging pathogenic mechanisms are at play. This parallels the notion that while the etiology may differ—be it through metabolic dysregulation or toxic alcohol exposure—the underlying genetic predispositions can drive similar pathological processes within the liver.

Investigations into somatic mutations have unveiled fascinating insights into adult liver tissues. It appears that clonal expansions of specific mutations in metabolic genes such as FOXO1, GPAM, and CIDEB can confer adaptive advantages that protect against lipotoxicity—a condition that arises from the accumulation of toxic lipid metabolites. These discoveries shed light on how certain genetic alterations can result in a survival advantage within the harsh environment of a steatotic liver, potentially altering the course of the disease.

Moreover, the phenomenon of clonal hematopoiesis of indeterminate potential (CHIP) has been correlated with an increased risk of chronic liver diseases, adding yet another layer of complexity. This condition not only impacts metabolic dysfunction-associated steatohepatitis (MASH) but is also implicated in elevating the risk of liver cancers that develop from prolonged liver injury and inflammation. The interplay between hematopoietic mutations and liver pathology opens new avenues for understanding how blood cell mutations can influence liver disease progression.

Inherited and somatic variants can directly modulate the risk of developing hepatocellular carcinoma through their roles in liver disease progression. Such variants may disrupt normal cellular signaling pathways involved in liver regeneration and damage repair. Research indicates that two major pathways—telomere maintenance and WNT signaling—are particularly important in the context of cancer-promoting mechanisms associated with these liver diseases.

Efforts to incorporate genetic knowledge into clinical practice are gaining traction, particularly with the application of polygenic risk scores (PRS). This approach promises to enhance risk stratification for individuals prone to steatotic liver diseases. However, the current iterations of polygenic risk scores face significant limitations, stemming from both the complexity of the diseases and the incomplete understanding of the interactions between multiple genetic and environmental factors.

The comprehensive study of steatotic liver diseases requires a multi-faceted approach, integrating genetic, epigenetic, and environmental perspectives to create a holistic understanding of disease mechanisms. Ongoing research endeavors aim to unravel the dialogue between genetic predisposition and environmental triggers, paving the way for novel therapeutic strategies that can target the root causes of these diseases rather than merely addressing the symptoms.

Furthermore, public health initiatives that focus on lifestyle modifications and preventive measures could play a crucial role in curbing the rising prevalence of these liver conditions. Increased awareness and education regarding the risks associated with metabolic diseases and excessive alcohol consumption can empower individuals to make informed health choices that mitigate their risk of developing liver diseases.

As the field continues to evolve, it’s imperative for researchers and clinicians to remain vigilant in tracking the long-term outcomes of individuals with identified genetic variants predisposing them to steatotic liver diseases. Understanding how these genetic insights influence treatment responses will be crucial for developing personalized medicine approaches that cater to the unique profiles of affected patients.

In summary, the landscape of steatotic liver diseases is characterized by a complex interplay of genetic factors, environmental influences, and pathogenic mechanisms. As researchers delve deeper into the genetic underpinnings and their implications for clinical outcomes, it is clear that a comprehensive understanding is essential for both better risk assessment and the development of effective treatment strategies.

Insights gained from these research undertakings provide an invaluable foundation for future studies aimed at elucidating the multifaceted nature of liver diseases. Ultimately, advancing our knowledge in this area presents an opportunity to significantly impact public health and improve clinical management strategies for steatotic liver diseases and their associated complications.

With the promising landscape of ongoing research and exploration in the realms of genomics and liver health, the future looks dynamic. As we aspire to unravel the complexities of steatotic liver diseases, collaboration across multiple disciplines will be crucial. Such efforts are expected to yield insights that can ultimately translate into tangible benefits for patients affected by these common yet often overlooked conditions.

Subject of Research: Steatotic Liver Diseases

Article Title: Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.

Article References:

Trépo, E., Zucman-Rossi, J. & Nault, JC. Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.
Nat Rev Gastroenterol Hepatol (2026). https://doi.org/10.1038/s41575-026-01175-y

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01175-y

Keywords: Steatotic liver diseases, metabolic dysfunction, alcoholic liver disease, hepatocellular carcinoma, PNPLA3, genetics, somatic mutations, polygenic risk scores, WNT signaling, liver health.

Hepatic stellate cells (HSCs), traditionally regarded as the primary cells responsible for liver fibrosis development, have now emerged as pivotal players in the transition from liver injury to cirrhosis and ultimately to liver cancer. The researchers discovered that EMP1+, a specific marker of activated hepatic stellate cells, significantly contributes to the fibrogenic response within the liver. This activation can result from a myriad of stimuli, including chronic viral hepatitis, alcohol consumption, and metabolic disorders. The intricate interplay of these factors sets the stage for the development of fibrosis, which becomes a precursor to HCC in susceptible individuals.

The significance of EMP1+ hepatic stellate cells emerges not only from their role in fibrosis but also in their capacity to influence the tumor microenvironment. The study demonstrated that these cells secrete various cytokines and growth factors that promote tumor growth and metastasis. The findings indicate that EMP1+ HSCs are not merely passive observers in the pathological landscape of the liver; rather, they actively contribute to creating a pro-tumorigenic environment, thereby facilitating the transition from non-cancerous liver disease to malignant tumors.

In a comprehensive analysis, the researchers employed advanced imaging techniques to visualize EMP1+ hepatic stellate cells within liver tissue samples from both animal models and human patients. By correlating these findings with clinical data, the team was able to establish a relationship between the abundance of EMP1+ cells and the severity of hepatic fibrosis. These results are particularly relevant as they suggest that the quantification of these cells may serve as a valuable prognostic biomarker, enabling clinicians to better predict the progression of liver disease towards HCC.

Moreover, the impact of EMP1+ hepatic stellate cells extends beyond their role in fibrosis and cancer progression; the study also identified their involvement in immune modulation within the liver. By altering the local immune context, these cells can skew the immune response, potentially allowing tumor cells to evade immune surveillance. This immune evasion is a hallmark of cancer biology and presents significant challenges for therapeutic interventions aimed at reinstating effective anti-tumor immunity.

In the quest for targeted therapies, understanding the molecular pathways activated within EMP1+ hepatic stellate cells could unveil innovative treatment strategies. The research highlights several key signaling pathways, including TGF-β and Hedgehog, which have previously been implicated in liver fibrosis and cancer progression. By inhibiting these pathways, it may be possible to disrupt the tumor-promoting activities of EMP1+ HSCs, thereby addressing both fibrosis and its oncogenic sequelae in a dual-targeted approach.

Additionally, the study’s findings emphasize the importance of early detection and monitoring of liver fibrosis. Given that HCC often develops silently over many years, identifying patients at risk through the assessment of EMP1+ hepatic stellate cells could lead to earlier interventions and potentially save lives. Implementing routine screenings and profiling patients for biomarkers associated with fibrogenesis may significantly reduce the burden of advanced liver disease.

Furthermore, the researchers note the potential for EMP1+ hepatic stellate cells to serve as a therapeutic target for novel drug development. As our understanding of liver pathology deepens, the prospect of developing drugs that specifically modulate the activity or recruitment of these cells opens exciting avenues for clinical research. Targeting the cellular mechanisms that drive hepatic fibrosis and cancer progression could revolutionize treatment approaches, offering hope to patients with limited treatment options.

The implications of this study extend beyond the realm of experimental findings; they underscore the critical need for interdisciplinary collaboration in addressing the multifaceted challenges posed by liver diseases. By integrating insights from molecular biology, immunology, and clinical research, scientists and clinicians can forge a comprehensive understanding of the pathways that govern the progression from fibrosis to HCC. Such collaborations will ultimately enhance patient care and outcomes in the growing population of individuals affected by liver diseases.

As the global prevalence of liver diseases continues to rise, driven in part by the increasing rates of obesity, viral hepatitis, and alcohol-related liver injury, the urgency for effective therapeutic strategies has never been more critical. The breakthrough findings from You, Huang, and Jiang could serve as a catalyst for renewed interest in the research surrounding hepatic stellate cells and their roles in liver pathology. By shifting the focus toward EMP1+ HSCs, researchers can open new frontiers in diagnosis, treatment, and patient prognosis.

In conclusion, the study highlights EMP1+ hepatic stellate cells as key mediators in the progression of liver fibrosis to hepatocellular carcinoma. Their dual role in promoting fibrosis and facilitating tumor growth marks them as critical players in the pathology of liver disease. The findings bear significant implications for both research and clinical practice, paving the way for innovative strategies to combat liver fibrosis and HCC, ultimately aiming to improve patient outcomes in this challenging field of medicine.

Subject of Research: The role of EMP1+ hepatic stellate cells in liver fibrosis progression to hepatocellular carcinoma and their potential as prognostic markers.

Article Title: EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis.

Article References:

You, J., Huang, Y., Jiang, C. et al. EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07454-7

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07454-7

Keywords: Hepatic stellate cells, liver fibrosis, hepatocellular carcinoma, EMP1+, tumor microenvironment, immune modulation, prognostic biomarkers, TGF-β, Hedgehog signaling.

Recent genetic research has illuminated the complex molecular underpinnings dictating individual susceptibility to steatotic liver disease. Genome-wide association studies have identified key allelic variants integral to disease pathogenesis. The variant PNPLA3 I148M (rs738409) emerges as the most potent genetic determinant, modulating lipid droplet metabolism within hepatocytes and hepatic stellate cells, thereby catalyzing steatosis and predisposing individuals to progressive fibrosis and oncogenesis. The TM6SF2 E167K (rs58542926) mutation impacts very-low-density lipoprotein secretion mechanisms, resulting in intracellular triglyceride retention and enhancing steatotic risk. Furthermore, the MBOAT7 rs641738 polymorphism interferes with phospholipid remodeling, fostering hepatic lipid accumulation. Conversely, the HSD17B13 rs72613567 variant exerts a protective role by mitigating steatosis and inflammatory responses, illustrating the intricate balance of genetic influences. These genotypic factors act synergistically with environmental elements such as obesity, insulin resistance, and sedentary lifestyle patterns to intensify hepatic injury, underpinning the multifactorial nature of MASLD.

A defining feature of MASLD progression is the complex cellular interplay precipitated by hepatocellular damage. Initial injury induces the release of damage-associated molecular patterns (DAMPs), reactive oxygen species (ROS), and extracellular vesicles, which collectively initiate a robust inflammatory cascade. Kupffer cells and recruited monocyte-derived macrophages amplify this response through an orchestrated secretion of cytokines and chemokines, fostering a pro-inflammatory milieu. Neutrophils, while traditionally implicated in injury propagation, exhibit dualistic roles by also facilitating resolution phases. Central to fibrosis is the activation of hepatic stellate cells (HSCs), which transdifferentiate into myofibroblast-like cells under the influence of IL-6–STAT3, YAP/TAZ, and TGF-β signaling pathways. Transcription factors JUNB and RUNX1/2 fine-tune this activation, whereas sirtuin 6 offers a counter-regulatory effect by deacetylating YAP/TAZ, thus repressing HSC activation. The extracellular matrix protein osteopontin, secreted by metabolically stressed hepatocytes, further propagates fibrogenesis, elucidating molecular links between metabolic dysfunction and stromal remodeling.

While metabolic and alcohol-associated liver diseases share overlapping pathological pathways, distinct mechanisms characterize ALD. Acetaldehyde toxicity serves as a hallmark of ALD pathogenesis, inducing oxidative stress and mitochondrial dysfunction. Genetic predisposition intersects with ALD largely through variants in PNPLA3, TM6SF2, and HSD17B13, emphasizing their broad role across steatotic liver disease spectra. Notably, ALD disrupts gut-liver axis homeostasis by impairing vitamin B6 biosynthesis and glutathione metabolism, exacerbating oxidative injury. Histologically, neutrophilic infiltration typifies alcoholic hepatitis and is driven by IL-8/CXCL8 dependent chemotaxis. Therapeutic strategies targeting chemokine receptors CXCR1/2 show promise in modulating neutrophil behavior, aiming to attenuate inflammatory damage while harnessing neutrophils’ paradoxical regenerative functions through macrophage crosstalk and hepatocyte proliferation.

The trajectory from chronic steatotic liver injury to hepatocellular carcinoma constitutes a continuum marked by cumulative genomic instability, fibrotic remodeling, and immune dysregulation. Epidemiological shifts reveal a decline in viral hepatitis-related HCC juxtaposed against a rise in metabolic and alcohol-induced hepatic cancers. Notably, MASH-HCC harbors distinct mutational landscapes with frequent alterations in ACVR2A, TERT, and CTNNB1 genes, contrasting with ALD-HCC’s prevalence of TP53 and ARID1A mutations. The tumor immune microenvironment in MASH-HCC is characterized by diminished macrophage and natural killer cell infiltration, indicative of impaired immune surveillance and potential challenges in immunotherapy responsiveness.

Preclinical investigations underscore the oncogenic utility of the PNPLA3 I148M variant, which potentiates HCC development under conditions of alcohol excess or metabolic stress. Intracellular communication via YAP-associated extracellular vesicles fosters tumor cell crosstalk and metastatic competence. Furthermore, altered bile acid homeostasis contributes substantially to T-cell exhaustion through cumulative oxidative and endoplasmic reticulum stress, highlighting metabolic dysregulation as a critical influencer of tumor immunity and progression.

Recent advances in therapeutics offer renewed hope in addressing steatotic liver disease and its sequelae. Thyroid hormone receptor-β (THR-β) agonists, exemplified by resmetirom, have achieved a milestone with FDA approval for MASH, demonstrating fibrosis improvement in approximately one-quarter of treated patients without exacerbating steatosis. This success validates thyroid hormone signaling as a pivotal metabolic intervention target. In parallel, GLP-1 based poly-agonists such as tirzepatide and retatrutide, which engage multiple incretin receptors, attain remarkable hepatic fat reductions up to 80% and achieve histological resolution in over 60% of cases, revolutionizing metabolic modulation strategies.

Moreover, fibroblast growth factor 21 (FGF21) analogues like pegozafermin and efruxifermin improve liver stiffness and attenuate fibrosis by augmenting mitochondrial performance and promoting lipid oxidation. Complementing these are farnesoid X receptor (FXR) agonists and bile acid modulators such as cilofexor and obeticholic acid, which restore bile acid equilibrium and mitigate inflammatory signaling. Additionally, FGF19 analogue aldafermin exhibits promising efficacy in reducing fibrosis in cirrhotic MASH, spotlighting the therapeutic importance of bile acid pathways.

In the arena of liver cancer therapeutics, immunotherapy-based regimens have transformed the landscape for advanced hepatocellular carcinoma. The adjuvant combination of atezolizumab and bevacizumab markedly extends recurrence-free survival following surgical resection. Frontline therapies including durvalumab plus tremelimumab (STRIDE protocol) and sintilimab plus bevacizumab biosimilar (ORIENT-32 trial) demonstrate superior overall survival compared with sorafenib, applicable across viral and non-viral etiologies, signaling a paradigm shift in oncological management.

Preventive and translational strategies underscore the critical need for personalized medicine approaches tailored to the heterogeneity of steatotic liver disease and its associated cancers. Integrative profiling encompassing genetic predispositions, metabolic states, and immune landscapes is vital for stratifying risk and optimizing intervention. Foundational public health measures—weight management, alcohol intake reduction, and glycemic control—remain indispensable pillars of risk mitigation. However, an era of molecularly targeted therapeutics promises to redefine disease trajectories and improve clinical outcomes substantially.

This comprehensive synthesis offered by Yang and colleagues delineates a robust framework interlinking steatotic liver disease pathogenesis with fibrosis and carcinogenesis. As the global burden advances, understanding this intricate biological network and exploiting emerging therapeutic targets will be paramount in addressing one of the most pressing hepatic health challenges of the 21st century.

Subject of Research: Steatotic liver disease pathogenesis, genetic determinants, cellular mechanisms, and therapeutic targets including disease progression to hepatocellular carcinoma.

Article Title: Steatotic liver disease and cancer: from pathogenesis to therapeutic targets

News Publication Date: Not specified in the source content (publication year 2025 indicated)

Web References: http://dx.doi.org/10.1136/egastro-2025-100218

Image Credits: By Xiaocheng Charlie Dong et al.

Keywords: Liver, Cancer